![]() |
市場調查報告書
商品編碼
1497654
3D 生物列印市場:按組件、技術和最終用戶分類 - 2024-2030 年全球預測3D Bioprinting Market by Component (3D Bioprinters, Bioinks), Technology (Extrusion-based Bioprinting, Inkjet-based Bioprinting, Laser-assisted Bioprinting), End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年3D生物列印市場規模為17.9億美元,預計2024年將達21.4億美元,2030年將達到63.9億美元,複合年成長率為19.89%。
3D 生物列印是一種將生物墨水與活細胞融合以創建類似組織的 3D 結構的技術。該過程在3D空間中逐層列印生物墨水和細胞的混合物。近年來,對3D生物列印技術的需求顯著成長,並已成為各種生物醫學應用的重要工具。疾病建模和組織工程是這項創新技術產生重大影響的兩個重要領域。全球慢性病數量迅速增加,以及對有效治療的需求不斷成長,正在推動對 3D 生物列印徹底改變醫療保健潛力的研究。此外,對個人化醫療應用的需求不斷成長,需要根據個人需求量身定製配方和治療方法,而 3D 生物列印在實現基於患者遺傳特徵和疾病特徵的客製化方面發揮關鍵作用。可擴展性是 3D 生物列印的關鍵問題。創造更大、更複雜的組織和器官需要提高列印過程的速度和精確度。然而,近年來,專注於開發用於 3D 生物列印應用的新型生醫材料的研究顯著增加。由天然和合成聚合物組成的新型生物墨水專為 3D 生物列印而設計。與傳統材料相比,這些生醫材料具有多種優勢,包括提高的生物相容性、可調節的機械性能和改善的細胞黏附性能,這些性能對於組織再生至關重要。
主要市場統計 | |
---|---|
基準年[2023] | 17.9億美元 |
預測年份 [2024] | 21.4億美元 |
預測年份 [2030] | 63.9億美元 |
複合年成長率(%) | 19.89% |
區域洞察
由於技術進步、成熟的製藥業和強大的研究基礎設施,美洲 3D 生物列印市場正在不斷成長。美國在美國地區佔有重要地位,擁有大量聯邦資金支持3D生物列印研發計劃。此外,北美的一些學術機構還建立了專用3D生物列印的研究設施。歐洲正在經歷慢性病的增加和人口老化,迫切需要更有效的藥物和個人化治療,並推動 3D 生物列印等生物技術的進步。在歐洲,德國、英國、法國和瑞典等國家已成為製藥領域採用3D生物列印技術的重要參與者。近年來,亞洲已成為器官移植的中心,隨著該地區人口的成長、預期壽命的延長以及慢性病和需要器官移植的疾病的數量相應增加,3D生物列印技術的進步正在迅速加速。此外,亞洲國家之間在醫學研究和技術方面區域合作的發展也對這一成長做出了重大貢獻。印度和中國在開發新穎解決方案方面擁有強大的立足點,並專注於 3D 生物列印技術,例如使用積層製造製程的生物人工器官。
FPNV定位矩陣
FPNV定位矩陣對於評估供應商在3D生物列印市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對 3D 生物列印市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在 3D 生物列印市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[189 Pages Report] The 3D Bioprinting Market size was estimated at USD 1.79 billion in 2023 and expected to reach USD 2.14 billion in 2024, at a CAGR 19.89% to reach USD 6.39 billion by 2030.
3D bioprinting is technology that merges bioinks and living cells to fabricate 3D structures resembling tissues. This process entails printing the bioink and cell mixture layer by layer in a three-dimensional space. In recent years, the demand for 3D bioprinting technologies has experienced significant growth, emerging as a vital tool in various biomedical applications. Disease modeling and tissue engineering are two critical areas in which this innovative technology is making a substantial impact. The burgeoning prevalence of chronic diseases globally and an increasing need for effective treatments have spurred researchers to explore the potential of 3D bioprinting in revolutionizing healthcare. Additionally, there has been a rising demand for personalized medicine applications that necessitate patient-specific drug formulations and treatments tailored to individual needs, where 3D bioprinting plays an essential role by allowing for customization based on patients' genetic profiles or disease characteristics. Scalability remains a significant challenge for 3D bioprinting as current technologies primarily focus on producing smaller tissue constructs. Creating larger and more complex tissues and organs requires advancements in both the speed and precision of printing processes. However, there has been a marked increase in research focused on developing novel biomaterials for 3D bioprinting applications in recent years. New bioinks composed of natural and synthetic polymers are explicitly designed for 3D bioprinting. These biomaterials offer several advantages over conventional materials, including enhanced biocompatibility, tunable mechanical properties, and improved cell adhesion characteristics, essentially required for tissue regeneration.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.79 billion |
Estimated Year [2024] | USD 2.14 billion |
Forecast Year [2030] | USD 6.39 billion |
CAGR (%) | 19.89% |
Regional Insights
The Americas 3D bioprinting market is growing due to technological advancement, a well-established pharmaceutical industry, and a robust research infrastructure. The United States witnessed a significant position in the American region with notable federal funding to support R&D projects in 3D bioprinting. Furthermore, several North American academic institutions have established dedicated 3D bioprinting research facilities. Europe has been witnessing an increasing prevalence of chronic diseases and an expanding geriatric population, creating an urgent need for more effective pharmaceutical drugs and personalized treatments, which has boosted the advancements in biotechnology, such as 3D bioprinting. Across Europe, countries such as Germany, the UK, France, and Sweden have emerged as critical players in adopting 3D bioprinting technologies within their pharmaceutical sectors. In recent years, Asia has emerged as a rising hub for organ transplantation, and 3D bioprinting advancements surged majorly due to the region's growing population, its increasing life expectancy, and the subsequent rise in chronic diseases and ailments requiring organ transplants. Furthermore, the development of regional collaboration among Asian countries in medical research and technology has significantly contributed to this growth. India and China have established a strong foothold in developing novel solutions and have specialized in 3D bioprinting technologies such as bioartificial organs using additive manufacturing processes.
Market Insights
The market dynamics represent an ever-changing landscape of the 3D Bioprinting Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the 3D Bioprinting Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the 3D Bioprinting Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Readily3D Unveils Advanced Bio-Inks for Precision 3D Bioprinting of Complex Tissues
Readily3D, a Swiss company specializing in 3D printing technologies, has announced the development of next-generation bio-inks for use in medical applications. This innovative product aims to enhance organ and tissue modeling by addressing the demand for high precision and compatibility in 3D bioprinting. By optimizing the viscosity of these bio-inks, Readily3D ensures smoother functioning in printing mechanisms, which is crucial for creating complex tissues such as those found in the human pancreas. This advancement promises to drive forward the capabilities in medical research and transplantation. It aligns with broader efforts in the industry to tailor bioprinting materials for specific medical needs, potentially revolutionizing patient-specific treatments. [Published On: 2024-05-23]
BIO INX Partners with Rousselot for Advancements in 3D Bioprinting Materials
BIO INX has partnered with Rousselot, a player in gelatin production, to elevate the field of 3D bioprinting. This partnership aims to leverage Rousselot's extensive expertise in gelatin formulation to revolutionize the development of high-quality bio inks. Such innovative bioinks are crucial for advancing 3D bioprinting technologies, which are pivotal in generating complex biological structures that can potentially lead to medical research and treatment breakthroughs. This partnership is set to combine BIO INX's cutting-edge bioprinting techniques with Rousselot's long-standing excellence in gelatin expertise, setting a promising path toward significant enhancements in the quality and performance of 3D printed products. [Published On: 2024-03-12]
Nexa3D Expands Market Footprint with the Acquisition of Essentium
Nexa3D, a player in ultra-fast stereolithography 3D printers, announced the acquisition of Essentium to broaden its capabilities and market reach in the high-speed extrusion (HSE) 3D printing sector. This transaction marks a significant step for Nexa3D in expanding its high-speed polymer 3D printers and materials portfolio. Essentium is renowned for its groundbreaking HSE 3D printing platform, which complements Nexa3D's existing product offerings and is expected to enhance its operational scale and innovation capacity in serving a growing global customer base. This acquisition aligns with Nexa3D's strategy to lead the additive manufacturing industry by integrating and optimizing production workflows and democratizing access to scalable additive manufacturing solutions. [Published On: 2024-01-12]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the 3D Bioprinting Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the 3D Bioprinting Market, highlighting leading vendors and their innovative profiles. These include 3D BioFibR, 3D Bioprinting Solutions, 3D Systems Corporation, Advanced Solutions, Inc., Aspect Biosystems Ltd., Avay Biosciences Private Limited, Axiom Space, Inc., Axolotl Biosystems Ltd., BICO Group AB, Brinter Inc., Cellbricks GmbH, CollPlant Biotechnologies Ltd., Cyfuse Biomedical K.K., Desktop Metal, Inc., Fluicell AB, FluidForm, Inc., FUJIFILM Corporation, GE HealthCare Technologies Inc., GeSiM, Inventia Life Science Pty Ltd., Medprin Regenerative Medical Technologies Co., Ltd., Merck KGaA, Organovo Holdings Inc., Pandorum Technologies Pvt. Ltd., Precise Bio Inc., Prellis Biologics, PrintBio, Inc, REGEMAT 3D S.L., regenHU Ltd., Regenovo Biotechnology Co., Ltd. by Shining 3D Tech Co., Ltd., ROKIT Healthcare Inc., TheWell Bioscience Inc., UPM-Kymmene Corporation, and UpNano GmbH.
Market Segmentation & Coverage